Physician profile
Peter Bw Knowlton
NPI 1740523604
$2,574.83
in general payments reported to CMS, 2019-2025
20 companies · $640 in 2025
The $640 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $224 · 2020: $140 · 2021: $195 · 2022: $298 · 2023: $462 · 2024: $616 · 2025: $640.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,718.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,717.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| New World Medical,INC. | $569.53 | 2021-2025 | Clearpath, Ahmed Glaucoma Valve, Kahook Dual Blade |
| Alcon Vision LLC | $475.26 | 2019-2025 | Rocklatan, Eysuvis, Clareon |
| Abbvie INC. | $289.84 | 2022-2025 | |
| Allergan, INC. | $254.46 | 2019-2022 | |
| Biotissue Holdings INC. | $114.60 | 2022-2024 | |
| Rayner Intraocular Lenses Limited | $113.50 | 2022-2024 | Rayone Emv, Omidria, Rayone Aspheric |
| Tarsus Pharmaceuticals, INC. | $112.10 | 2024-2025 | Xdemvy |
| Sun Pharmaceutical Industries INC. | $98.48 | 2019-2025 | |
| Ocular Therapeutix, INC. | $87.26 | 2019-2023 | Dextenza |
| Bausch & Lomb Americas INC. | $86.86 | 2023-2025 | Miebo, Xiidra, Lotemax Sm |
| Oyster Point Pharma, INC. | $74.36 | 2022-2024 | Tyrvaya, Ryzumvi |
| Carl Zeiss Meditec, INC. | $64.71 | 2019 | |
| Sight Sciences, INC. | $50.10 | 2021-2022 | |
| Harrow Eye, LLC | $48.32 | 2024-2025 | Iheezo, Vevye |
| Novartis Pharmaceuticals Corporation | $30.73 | 2020-2023 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $24.33 | 2019 | |
| Kala Pharmaceuticals, INC. | $24.05 | 2021 | |
| Horizon Therapeutics Plc | $22.59 | 2019 | |
| Aerie Pharmaceuticals, INC. | $17.78 | 2020 | |
| Mallinckrodt Enterprises LLC | $15.97 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Knowlton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.